Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PERMAD
- 05 Jun 2018 Results from the first part of the trial presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.